A large number of studies has provided information on the clinical characteristics of subjects with isolated office or white-coat hypertension (WCH). [1][2][3][4][5][6][7][8][9][10][11][12][13] However, information is limited on whether and to what extent WCH is affected by antihypertensive treatment. The limitation includes the effect of treatment on blood pressure (BP) because although some studies have reported that in WCH treatment lowers office BP, 14 other studies deny that this occurs, quoting as an example the case of spurious resistant hypertension, that is, a condition in which a normal ambulatory BP (ABP) is accompanied by an office BP that remains elevated despite multiple drug treatment. 15,16 Furthermore, the effect of treatment on ABP values of WCH individuals is by no means clear because the reports range from a marked ABP fall to an ABP fall with some drugs only to no ABP fall at all. 14,[17][18][19][20][21][22][23][24][25][26][27] Previous studies on the BP effects of antihypertensive treatment in WCH have usually assessed ABP by just one 24-hour recording, sometimes without a baseline reference value.14,28 Primary aim of the present study has been to address the issue in a more adequate fashion by taking advantage of the unique data provided by the European Lacidipine Study on Atherosclerosis (ELSA) trial, 29 the only prospective antihypertensive treatment trial in which all patients with moderate elevations of both systolic BP (SBP) and diastolic BP (DBP) had office and ABP measured (1) before randomization to treatment and (2) at 6-month (office BP) and 12-month (ABP) intervals during treatment over a follow-up of 4 years. The multiple office and ABP measurements during the treatment period allowed us to more properly address also other issues relevant to WCH, such as the modification with time of the difference between office and ABP, often defined as the WC effect, 14,30 and the effect of treatment on within 24 hours and visit-to-visit BP variability (short-and long-term variability) of WCH vis-à-vis sustained hypertensive individuals. 31 These issues have never been addressed before.
Methods
Study Design and PatientsThe design and methods of the ELSA trial have been described in detail elsewhere. 29 Briefly, ELSA was a prospective, randomized, double-blind trial comparing the effects of long-term β-blocker or calcium antagonist treatment on the progression of carotid intimamedia thickness in mild-to-moderate essential hypertension. Randomization criteria were (1) an age between 45 and 75 years, Abstract-Limited evidence is available on the extent and frequency by which antihypertensive treatment lowers office blood pressure (BP) in white-coat hypertension (WCH). Data are even more scanty and discrepant on the corresponding effect on ambulatory BP (ABP). In the hypertensive patients of the European Lacidipine Study on Atherosclerosis (ELSA), office and ABP were measured before treatment and at 6-month (office BP) or 12-month (ABP) intervals during the 4-year administration of calcium chann...